FDA grants fast track status for GC Biopharma and Novel Pharma’s GC1130A

Sanfilippo syndrome Type A is a rare genetic disorder that leads to central nervous system damage due to the accumulation of heparan sulfate. Credit: Pete Linforth from Pixabay.